104 related articles for article (PubMed ID: 12218223)
1. Evaluation of soluble Fas ligand as a serological marker for melanoma.
Melzani G; Bugari G; Parrinello G; Mori G; Manganoni Au; De Panfilis G
Dermatology; 2002; 205(2):111-5. PubMed ID: 12218223
[TBL] [Abstract][Full Text] [Related]
2. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas and soluble Fas-ligand in children with Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Masri C; Proulx F; Toledano B; Clermont MJ; Mariscalco MM; Seidman EG; Carcillo J
Am J Kidney Dis; 2000 Oct; 36(4):687-94. PubMed ID: 11007669
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel S; Rappl G; Tilgen W; Reinhold U
Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
Clin Rheumatol; 2007 Mar; 26(3):393-400. PubMed ID: 16972019
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
Lim SC
Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
[TBL] [Abstract][Full Text] [Related]
9. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
12. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
Kacprzyk F
Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
[TBL] [Abstract][Full Text] [Related]
13. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
14. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract][Full Text] [Related]
15. [The expression of Fas antigen and plasma levels of sFas and sFasL in patients with aplastic anemia].
Ren C; Zhang M; Xu C; Zhang T
Zhonghua Xue Ye Xue Za Zhi; 2000 Apr; 21(4):198-200. PubMed ID: 11876982
[TBL] [Abstract][Full Text] [Related]
16. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease.
Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H
Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
